SCHEDULE 13G: AbbVie Discloses 9.0% Stake in Xilio Therapeutics, Signaling Strategic Investment

AbbVie Inc. has disclosed a significant 9.0% beneficial ownership stake in Xilio Therapeutics, Inc., acquiring over 4.3 million shares of common stock.

Summary

• AbbVie Inc. has filed a Schedule 13G, reporting beneficial ownership of 4,347,826 shares of Common Stock in Xilio Therapeutics, Inc.
• This ownership represents 9.0% of Xilio Therapeutics' outstanding Common Stock.
• The shares were issued to AbbVie Inc. on February 11, 2025.
• The calculation of the percentage ownership is based on 43,958,074 shares of Common Stock outstanding as of November 1, 2024, plus the 4,347,826 shares issued to AbbVie Inc.
• AbbVie Inc. holds sole voting power and sole dispositive power over all 4,347,826 shares.
• The filing certifies that the securities were not acquired for the purpose of changing or influencing the control of Xilio Therapeutics, Inc.

Sentiment

Score: 7

Explanation: The acquisition of a significant stake by a major pharmaceutical company like AbbVie is generally a positive signal for a smaller biotech firm like Xilio Therapeutics, indicating potential validation and capital infusion.

Positives

• A major pharmaceutical company, AbbVie Inc., has taken a significant 9.0% equity stake in Xilio Therapeutics, Inc., which can be interpreted as a vote of confidence in Xilio's potential.
• The issuance of 4,347,826 shares to AbbVie Inc. indicates a capital infusion for Xilio Therapeutics, providing additional funding for its operations and development.

Future Outlook

The document does not provide forward-looking statements or guidance regarding Xilio Therapeutics' future performance or strategic direction, beyond the passive nature of AbbVie's investment.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11." (Scott T. Reents, Executive Vice President, Chief Financial Officer, AbbVie Inc.)

Industry Context

This filing indicates a strategic investment by a large, established pharmaceutical company (AbbVie) into a smaller biotechnology firm (Xilio Therapeutics). Such investments are common in the life sciences sector, often signaling potential future collaborations, partnerships, or a validation of the smaller company's technology or pipeline by a larger industry player.

Stakeholder Impact

• Shareholders of Xilio Therapeutics: The entry of a major institutional investor like AbbVie could be viewed positively, potentially increasing investor confidence and liquidity.
• Xilio Therapeutics: The company benefits from the capital raised through the issuance of shares to AbbVie, which can support its ongoing research and development efforts.

Key Dates

Keywords

AbbVie Inc., Xilio Therapeutics Inc., Schedule 13G, Beneficial Ownership, Equity Stake, Common Stock, Pharmaceutical, Biotechnology, Investment, SEC Filing